:
Cancer continues to be one of the deadliest diseases that adversely impacts the large population of the world. A stack of
scientific documents reflects a huge number of potent plant-based anticancer drugs such as curcumin (CUR), podophyllotoxin, camptothecin (CPT), vincristine, vinblastine, paclitaxel (PTX), etc. that have been integrated into the modern practice of cancer treatment.
The demand for natural products raises exponentially as they are generally considered to be safe, and devoid of critical toxic effects at
the therapeutic dose when compared to their synthetic counterparts. Despite rising interest towards the potent phytoconstituents, formulation developer faces various challenges in drug development processes such as poor water solubility, low bioavailability, marginal permeability, and nonspecific drug delivery at the target site, etc. Further, adverse drug reaction and multidrug resistance are
other critical issues need to be addressed. Nanomedicines owing to their unique structural and functional attributes help to fix the
above challenges for improved translational outcomes. This review summarises the prospects and challenges of a nanotechnologybased drug delivery approach for the delivery of plant-based anticancer drugs.
The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs
